Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT<sub>4</sub> agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study
Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT<sub>4</sub> agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT<sub>4</sub> agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study have?
Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT<sub>4</sub> agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study has 111 citations in the OpenAlex counts ScholarIQ stores.
When was Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT<sub>4</sub> agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study published?
Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT<sub>4</sub> agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study has 2010 year in the ScholarIQ index.
What is the open-access status of Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT<sub>4</sub> agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study?
Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT<sub>4</sub> agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study has closed oa status in the ScholarIQ index.
What is the DOI of Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT<sub>4</sub> agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study?
The DOI for Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT<sub>4</sub> agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study is on the source record.
What is the PMID of Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT<sub>4</sub> agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study?
The PMID for Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT<sub>4</sub> agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study is on the source record.
What is the OpenAlex record for Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT<sub>4</sub> agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study?
The OpenAlex for Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT<sub>4</sub> agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study is on the source record.